Screener
Monte Rosa Therapeutics, Inc. GLUE Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenue.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s deferred revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) reported deferred revenue of $105.62M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s deferred revenue increased by 1210.6% year-over-year, from $8.06M to $105.62M.
- What does deferred revenue mean?
- Deferred Revenue as reported by Monte Rosa Therapeutics, Inc. Common Stock.
Ask your AI about Monte Rosa Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude